Dr Magda Papadaki, is Head of Product and Process Innovation for ABPI. She is responsible for UK’s pharma strategy in innovative products and ATMPs, new Synthetic Biology R&D tools and novel platforms for their production and regulatory/clinical assessment. She is also ABPI’s EFPIA/IMI liaison in the ATMP and Adaptive Pathways/RWE working groups. Before joining ABPI, Magda was a Lead Technologist for the Innovate UK Regenerative Medicine program, the UK Government’s Science and Technology Funding arm. A stem cell and gene therapy scientist by training, combines over a decade in research, with regulatory and business experience in the EU and US. She is a subject matter expert on new iterative product development and approval approaches and was member of the NEWDIGS consortium on the Adaptive Licensing paradigm in MIT, Boston, MA. Magda has worked extensively in the global space of public-private partnerships, including the EU Innovative Medicines Initiative (IMI) and the US/FDA Critical Path initiative. Her industry experience was with Novartis, as DRA and QA/QC Director for Greece and Cyprus. She holds a PhD in Gene Therapy and Stem Cells, an MPhil in Bioscience Enterprise from the University of Cambridge, UK and MSc in Pharmacology from the University of Oxford, UK.